Skip to main content
SpringerLink
Log in

Diabetes Technology in People with Type 2 Diabetes: Novel Indications

  • REVIEW
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Diabetes technology has been continuously evolving. Current versions of continuous glucose monitors (CGM) use minimally invasive designs, monitor glucose values with high accuracy, and can be used to guide insulin dosing. Extensive evidence supports the use of diabetes technology for monitoring and insulin administration in people with type 1 diabetes. However, there is emerging evidence for people with type 2 diabetes. In this review, we present the different technological devices used to monitor glucose and deliver insulin and the evidence supporting their use in people with type 2 diabetes.

Recent Findings

The use of CGMs in people with type 2 diabetes treated with insulin or non-insulin therapies has been associated with improvements in glycemic control and time spent in hypoglycemia. Smart insulin pens and smart connected devices are options to track compliance and guide insulin delivery in people who do not require insulin pump therapy. Mechanical patch pumps can be used to reduce the burden of multiple daily insulin injections. Automated insulin delivery algorithms improve glycemic control without an increase in hypoglycemia.

Summary

The use of technology in the management of type 2 diabetes generates glycemic data previously inaccessible, reduces barriers for insulin initiation, improves glycemic control, tracks adherence to therapy, and improves user satisfaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53. https://doi.org/10.1016/S0140-6736(98)07019-6.

    Article  Google Scholar 

  2. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431.

    Article  CAS  PubMed  Google Scholar 

  3. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008;358(24):2560–2572 https://doi.org/10.1056/NEJMoa0802987

  4. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. https://doi.org/10.1016/S0140-6736(10)60576-4.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. https://doi.org/10.1136/bmjmed-2022-000372.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lingvay I, Agarwal S. A revolution in obesity treatment. Nat Med. 2023;29(10):2406–8. https://doi.org/10.1038/s41591-023-02538-7.

    Article  CAS  PubMed  Google Scholar 

  7. Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults 1999–2018 N Engl J Med. 2021; 384(23):2219–2228 https://doi.org/10.1056/NEJMsa2032271

  8. • Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology Diabetes Res Clin Pract. 2020;170:108502. https://doi.org/10.1016/j.diabres.2020.108502. This article covers the salient advances in CGM technology over time and provides tips on implementation of CGM in the medical office.

  9. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562–78. https://doi.org/10.1177/193229681300700234.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Das SK, Nayak KK, Krishnaswamy PR, et al. Review—electrochemistry and other emerging technologies for continuous glucose monitoring devices. ECS Sensors Plus. 2022;1(3) https://doi.org/10.1149/2754-2726/ac7abb

  11. Heinemann L, Schoemaker M, Schmelzeisen-Redecker G, et al. Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space. J Diabetes Sci Technol. 2020;14(1):135–50. https://doi.org/10.1177/1932296819855670.

    Article  PubMed  Google Scholar 

  12. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert. Diabetes Technol Ther. 2019;21(4):155–8. https://doi.org/10.1089/dia.2018.0359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dexcom G6 User Guide. https://s3-us-west-2.amazonaws.com/dexcompdf/Downloads+and+Guides+Updates/LBL017451+Using+Your+G6%2C+G6%2C+UK%2C+EN%2C+mmol.pdf. Accessed 20 Nov 2023

  14. Dexcom G7 User Guide. https://s3.us-west-2.amazonaws.com/dexcompdf/Downloads+and+Guides+Updates/AW00046-05+UG+G7+OUS+en+MMOL.pdf. Accessed 20 Nov 2023

  15. FreeStyle Libre 2 User Manual. https://freestyleserver.com/Payloads/IFU/2023/q3/ART48230-001_rev-A-web.pdf. Accessed 20 Nov 2023

  16. FreeStyle Libre 3 User Manual. https://freestyleserver.com/payloads/ifu/2023/q3/ART41641-001_rev-A-web.pdf. Accessed 20 Nov 2023

  17. Guardian Sensor 3 User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian_Sensor_3_User_Guide_Jun-2023.pdf. Accessed 20 Nov 2023

  18. Guardian Sensor 4 User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian_4_sensor_user_guide.pdf Accessed 20 Nov 2023.

  19. Medtronic News. Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design. https://news.medtronic.com/2023-09-21-Medtronic-Diabetes-announces-CE-Mark-for-new-Simplera-TM-CGM-with-disposable-all-in-one-design. Accessed 20 Nov 2023

  20. Eversense E3 User Guide. https://www.eversensediabetes.com/wp-content/uploads/LBL-6002-01-001-Rev-B_Eversense-E3-User-Guide_mgdL_R1.pdf. Accessed November 20, 2023.

  21. Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol. 2017;11(1):59–67. https://doi.org/10.1177/1932296816662047.

    Article  CAS  PubMed  Google Scholar 

  22. Roussel R, Riveline JP, Vicaut E, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021;44(6):1368–76. https://doi.org/10.2337/dc20-1690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8:1 e001115. https://doi.org/10.1136/bmjdrc-2019-001115.

    Article  PubMed  Google Scholar 

  24. Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diab Vasc Dis Res. 2021;18(4):14791641211021374. https://doi.org/10.1177/14791641211021374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73. https://doi.org/10.1007/s13300-016-0223-6.

    Article  CAS  PubMed  Google Scholar 

  26. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74. https://doi.org/10.7326/M16-2855.

    Article  PubMed  Google Scholar 

  27. Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262–72. https://doi.org/10.1001/jama.2021.7444.

    Article  CAS  PubMed  Google Scholar 

  28. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178–84. https://doi.org/10.2337/dc18-0166.

    Article  CAS  PubMed  Google Scholar 

  29. Ehrhardt N, Al ZE. Continuous glucose monitoring as a behavior modification tool. Clin Diabetes. 2020;38(2):126–31. https://doi.org/10.2337/cd19-0037.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Aronson R, Brown RE, Chu L, et al. Impact of flash glucose monitoring in people with type 2 diabetes inadequately controlled with non-insulin antihyperglycaemic therapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab. 2023;25(4):1024–31. https://doi.org/10.1111/dom.14949.

    Article  CAS  PubMed  Google Scholar 

  31. InPen User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/InPen-user-guide.pdf Accessed 20 Nov 2023

  32. MacLeod J, Im GH, Smith M, Vigersky RA. Shining the spotlight on multiple daily insulin therapy: real-world evidence of the InPen™ smart insulin pen. Diabetes Technol Ther. 2023 https://doi.org/10.1089/dia.2023.0365. https://doi.org/10.1089/dia.2023.0365

  33. Tempo Smart Button User Guide. https://pi.lilly.com/us/tempo-smart-button-ug.pdf Accessed 2 Dec 2023

  34. Bigfoot Unity System User Guide. https://f.hubspotusercontent40.net/hubfs/5085144/PDFs/Bigfoot%20Unity%E2%84%A2%20System%20User%20Guide.pdf. Accessed 2 Dec 2023

  35. ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT05088265?term=NCT05088265. Accessed 9 Dec 2023

  36. Malone JK, Beck R, Tillman J, et al. 936-P:Three-month interim analysis from the prospective Bigfoot Unity Real World Study (BURST). Diabetes. 2023; 72(Supplement_1): 936–P https://doi.org/10.2337/db23-936-P

  37. Galindo RJ, Ramos C, Cardona S, et al. Efficacy of a smart insulin pen cap for the management of patients with uncontrolled type 2 diabetes: a randomized cross-over trial. J Diabetes Sci Technol. 2023;17(1):201–7. https://doi.org/10.1177/19322968211033837.

    Article  CAS  PubMed  Google Scholar 

  38. Ananthanarayanan V, Mithun Haridas TP, Naveen R, et al. Reliable and affordable embedded system solution for continuous blood glucose maintaining system with wireless connectivity to blood glucose measuring system. IJCA Proceedings on Amrita International Conference of Women in Computing. 2013; AICWIC(2):36–43

  39. Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72. https://doi.org/10.1016/S0140-6736(14)61037-0.

    Article  CAS  PubMed  Google Scholar 

  40. Boughton CK, Hovorka R. Automated insulin delivery in adults. Endocrinol Metab Clin North Am. 2020;49(1):167–78. https://doi.org/10.1016/j.ecl.2019.10.007.

    Article  PubMed  Google Scholar 

  41. •• Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice Endocr Rev 2023;44(2):254–280. https://doi.org/10.1210/endrev/bnac022. This article provides an in-depth data about the evidence of AID use, practical tips on initiating AID, and user training tips.

  42. V-Go User Guide. https://www.go-vgo.com/wp-content/uploads/2020/09/ART-1361-rev.B-V-Go-IFU.pdf. Accessed 2 Dec 2023

  43. Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. J Health Econ Outcomes Res. 2019 6(2):70–83. https://doi.org/10.36469/9731

  44. Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M Multicenter real-world assessment of the effectiveness of V-Go wearable insulin delivery device in adult patients with type 2 diabetes (ENABLE Study): a retrospective analysis. Med Devices (Auckl). 2020;13:283–291 https://doi.org/10.2147/MDER.S265869

  45. Grunberger G, Rosenfeld CR, Bode BW, et al. Effectiveness of V-Go® for patients with type 2 diabetes in a real-world setting: a prospective observational study. Drugs Real World Outcomes. 2020;7(1):31–40. https://doi.org/10.1007/s40801-019-00173-8.

    Article  PubMed  Google Scholar 

  46. Cequr Simplicity user guide. https://myceqursimplicity.com/wp-content/uploads/User-Guide.pdf. Accessed 3 Dec 2023

  47. Bergenstal RM, Peyrot M, Dreon DM, et al. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther. 2019;21(5):273–85. https://doi.org/10.1089/dia.2018.0298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167–73. https://doi.org/10.1177/19322968211016513.

    Article  CAS  PubMed  Google Scholar 

  49. Zraick V, Dreon D, Naik R, et al. Patient user experience evaluation of bolus patch insulin delivery system. https://www.jnj.com/sites/default/files/pdf/ada-mae-poster-5-23-16_final.pdf. Accessed 2 Dec 2023

  50. Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198–207. https://doi.org/10.2337/cd22-0034.

    Article  PubMed  Google Scholar 

  51. Omnipod GOTM. https://www.omnipod.com/what-is-omnipod/omnipod-go. Accessed 2 Dec 2023

  52. Tandem T. Slim X2 user guide. https://www.tandemdiabetes.com/docs/default-source/user-guide/aw-1007704_b-user-guide-mobile-bolus-tslim-x2-control-iq-7-6-mgdl-artwork-weba4e76d9775426a79a519ff0d00a9fd39.pdf?sfvrsn=18a507d7_231. Accessed 3 Dec 2023

  53. Forlenza GP, Carlson AL, Galindo RJ, et al. Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the medicare and medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther. 2022;24(11):814–23. https://doi.org/10.1089/dia.2022.0206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Habif S, Constantin A, Mueller L, et al. 126-LB: glycemic outcomes for people with type 1 and type 2 diabetes using control-IQ technology: real-world data from early adopters. Diabetes. 2020, 69(Supplement_1): 126–LB https://doi.org/10.2337/db20-126-lb

  55. ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT04233229. Accessed 9 Dec 2023

  56. ClinicalTrials.Gov.https://clinicaltrials.gov/study/NCT06024928. Accessed 9 Dec 2023

  57. ClinicalTrials.Gov.https://clinicaltrials.gov/study/NCT05785832. Accessed 9 Dec 2023

  58. Medtronic MiniMed 780G User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed-780G-system-user-guide-with-Guardian-4-sensor.pdf. Accessed 3 Dec 2023

  59. What is Meal DetectionTM technology?. The LOOP Blog. Published July 19, 2023. https://www.medtronicdiabetes.com/loop-blog/meal-detection-technology/. Accessed 9 Dec 2023

  60. ClinicalTrials.Gov. https://clinicaltrials.gov/study/NCT05238142. Accessed 9 Dec 2023

  61. Omnipod 5 User Guide. https://www.omnipod.com/sites/default/files/Omnipod-5_User-guide.pdf. Accessed 3 Dec 2023

  62. Davis GM, Peters AL, Bode BW, et al. Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care. 2023;46(4):742–50. https://doi.org/10.2337/dc22-1915.

    Article  PubMed  PubMed Central  Google Scholar 

  63. BetaBionics iLet User Guide. https://www.betabionics.com/wp-content/uploads/LA000079_C-iLet-Bionic-Pancreas-System-HCP-Guide.pdf. Accessed 2 Dec 2023

  64. Peters AL, Ahmann AJ, Hirsch IB, Raymond JK. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc. 2018;2(11):1214–25. https://doi.org/10.1210/js.2018-00262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27(6):505–37. https://doi.org/10.1016/j.eprac.2021.04.008.

    Article  PubMed  Google Scholar 

  66. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002.

    Article  PubMed  PubMed Central  Google Scholar 

  67. •• ElSayed NA, Aleppo G, Aroda VR, et al. on behalf of the American Diabetes Association. 7. Diabetes technology: standards of care in diabetes—2023. Diabetes Care. 2023; 46(Supplement_1): S111–S127. https://doi.org/10.2337/dc23-S007. Extensive guideline recommendation on the use of diabetes technology.

  68. •• Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023;29(5):305–340. https://doi.org/10.1016/j.eprac.2023.02.001. Extensive guideline recommendation on the use of diabetes technology.

Download references

Author information

Authors and Affiliations

  1. The University of Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA

    Shubham Agarwal, Amy V. Shah & Marconi Abreu

  2. University of Miami Miller School of Medicine, 1450 NW 10th Ave, Miami, FL, 33136, USA

    Rodolfo J. Galindo

Authors
  1. Shubham Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodolfo J. Galindo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy V. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marconi Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.J.G. and M.A. prepared the broad outline of the manuscript. S.A., R.J.G., A.V.S., and M.A. equally contributed with literature review and writing the main manuscript. All the authors were involved in proof-reading and editing of this manuscript.

Corresponding author

Correspondence to Shubham Agarwal.

Ethics declarations

Competing Interests

The authors did not receive support from any organization for the submitted work.

Human/Animal Studies and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agarwal, S., Galindo, R.J., Shah, A.V. et al. Diabetes Technology in People with Type 2 Diabetes: Novel Indications. Curr Diab Rep 24, 85–95 (2024). https://doi.org/10.1007/s11892-024-01536-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-024-01536-4

Keywords

Search

Navigation